Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Muscle-invasive Bladder Cancer
NCT03234153Phase 2Terminated
- Sponsor
- Insel Gruppe
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in muscle-invasive bladder cancer (MIBC), sponsored by Insel Gruppe. Primary endpoint: Objective Response Rate at 16 weeks. Started Jul 2018; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03234153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234153.